Stockscreener 앱 받기
5.21
6.63%
-0.37
전일 마감가:
$5.58
열려 있는:
$5.59
하루 거래량:
6.74M
Relative Volume:
1.82
시가총액:
$1.60B
수익:
$248.37M
순이익/손실:
$11.74M
주가수익비율:
104.20
EPS:
0.05
순현금흐름:
$18.24M
1주 성능:
-10.94%
1개월 성능:
-11.84%
6개월 성능:
+31.57%
1년 성능:
-13.31%
1일 변동 폭
$5.19
$5.61
1주일 범위
$5.19
$5.845
52주 변동 폭
$3.3812
$6.51
맨카인드 Stock (MNKD) Company Profile
명칭
Mannkind Corp
전화
818-661-5000
주소
1 CASPER STREET, DANBURY, CA
MNKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.21 | 1.71B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
맨카인드 Stock (MNKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-10-10 | 개시 | Leerink Partners | Outperform |
| 2025-07-16 | 재개 | H.C. Wainwright | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-10 | 개시 | Wedbush | Outperform |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-12-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-10 | 개시 | Wedbush | Outperform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 개시 | Oppenheimer | Outperform |
| 2019-10-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2018-02-28 | 다운그레이드 | Maxim Group | Hold → Sell |
| 2017-11-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-10 | 개시 | H.C. Wainwright | Buy |
| 2017-10-06 | 재확인 | Maxim Group | Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-05-10 | 재확인 | Piper Jaffray | Underweight |
| 2016-05-10 | 재확인 | RBC Capital Mkts | Underperform |
| 2016-01-06 | 재확인 | Piper Jaffray | Underweight |
| 2016-01-06 | 재확인 | RBC Capital Mkts | Underperform |
| 2015-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | 다운그레이드 | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-05-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 재확인 | MLV & Co | Hold |
| 2015-04-16 | 재확인 | RBC Capital Mkts | Outperform |
모두보기
맨카인드 주식(MNKD)의 최신 뉴스
MannKind (NASDAQ:MNKD) Shares Down 6.4%Here's What Happened - MarketBeat
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile - Yahoo Finance
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz
MannKind (NASDAQ:MNKD) Raised to Strong-Buy at Zacks Research - MarketBeat
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
MannKind Corporation (MNKD) Stock Analysis: 66.57% Potential Upside Captivates Investors - DirectorsTalk Interviews
Deltec Asset Management LLC Takes $3.89 Million Position in MannKind Corporation $MNKD - MarketBeat
MannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: Stuart Tross Sells 47,006 Shares of MannKind Corp (MNKD) - GuruFocus
Mannkind’s chief people officer sells $297k in stock By Investing.com - Investing.com South Africa
Mannkind’s chief people officer sells $297k in stock - Investing.com
MannKind Corp stock hits 52-week high at 6.33 USD By Investing.com - Investing.com Nigeria
Pharma news weekly roundup - The Pharma Letter
MannKind (NASDAQ:MNKD) Insider Stuart Tross Sells 47,006 Shares - MarketBeat
Is MannKind Corporation stock affected by interest rate hikesMarket Trend Review & Consistent Profit Alerts - ulpravda.ru
How MannKind Corporation stock reacts to Fed rate cutsJuly 2025 Snapshot & Safe Swing Trade Setups - ulpravda.ru
Why MannKind Corporation stock is favored by top institutions2025 Biggest Moves & High Yield Equity Trading Tips - ulpravda.ru
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report - Stocktwits
Boeing’s CEO Tells Staff ‘Important Work Ahead’ To Continue Its Turnaround: Report - Stocktwits
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 - Stocktwits
How MannKind Corporation stock reacts to global recession fears2025 Volatility Report & Risk Managed Trade Strategies - Улправда
MannKind stock jumps on 2026 catalysts - Investing.com
Can MannKind Corporation stock deliver surprise earnings beatInsider Buying & Advanced Technical Analysis Signals - ulpravda.ru
MannKind Corp stock hits 52-week high at 6.33 USD - Investing.com
MannKind outlines 2026 growth drivers with key FDA decisions ahead - Investing.com
MannKind Provides Business Updates and 2026 Growth Drivers - Yahoo Finance
MannKind (NASDAQ:MNKD) Reaches New 52-Week HighWhat's Next? - MarketBeat
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - MSN
Calamos Advisors LLC Acquires New Position in MannKind Corporation $MNKD - MarketBeat
MannKind Corp Is Suddenly Everywhere – Is MNKD the Next Sleeper Stock You’ll Regret Ignoring? - AD HOC NEWS
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
MannKind (MNKD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MNKD (MannKind) ROCE % : 17.64% (As of Sep. 2025) - GuruFocus
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years - Yahoo Finance
180 Wealth Advisors LLC Increases Stock Position in MannKind Corporation $MNKD - MarketBeat
How Pediatric FUROSCIX Expansion And New Patents At MannKind (MNKD) Has Changed Its Investment Story - simplywall.st
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? - Stocktwits
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - Yahoo Finance
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - The Motley Fool
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
FDA approves FUROSCIX for pediatric patients weighing 43kg or more By Investing.com - Investing.com South Africa
FDA approves FUROSCIX for pediatric patients weighing 43kg or more - Investing.com
MannKind Corporation Announces FDA Approval of FUROSCIX® for Pediatric Use and Patent Issuance for FUROSCIX ReadyFlow™ Autoinjector - Quiver Quantitative
Shot for fluid buildup could help kids and work at home in 10 seconds - Stock Titan
MannKind Shares FUROSCIX® Business Updates - Yahoo Finance
Can MannKind Corporation stock hit record highs again2025 Valuation Update & Consistent Growth Stock Picks - ulpravda.ru
Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Insider Sell: Michael Castagna Sells 65,804 Shares of MannKind C - GuruFocus
맨카인드 (MNKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):